Latest News

As artificial intelligence–based tools grow in popularity, helping patients know when to use digital tools and when to ask a clinician is essential.

As case counts rise in the current outbreak, pharmacists must be prepared to counsel patients regarding management, including pediatric patients who require unique considerations.

Decode carcinogens: IARC hazard vs risk, what "possibly" means, and how pharmacists ease aspartame, meat, and phone fears.

Garetosmab-grts cut new heterotopic ossification lesions by 90% or more at 56 weeks in the phase 3 OPTIMA trial.

Intismeran autogene plus pembrolizumab significantly improved recurrence-free and distant metastasis-free survival over pembrolizumab alone.

Findings published in Lancet Child & Adolescent Health arrive as a new US executive order shifts rotavirus vaccination to shared clinical decision-making.

The patch detected fentanyl and automatically delivered dose-responsive naloxone in laboratory and mouse studies, offering a potential strategy for addressing unwitnessed opioid overdoses.

New data link T2DM and prediabetes to more numerous, more severe symptoms, especially postmenopause.

Learn how common meds, immunosuppressants, steroids, anti-CD20 biologics, and antivirals change vaccine timing for the best.

A nationally representative analysis found serologic immunity to hepatitis A and B was limited among US adults, including populations at elevated risk.

In an interview with Pharmacy Times, Scott Soefje, PharmD, MBA, BCOP, FCCP, FHOPA, discussed how Inlexzo and increasingly complex urologic cancer therapies are driving closer coordination between urology and oncology pharmacy.

New ACC statement urges pharmacists to weigh cognition and frailty in every older adult's cardiovascular regimen.

Without an identifiable cure, pharmacists must prioritize prompt diagnosis and individualized symptom management.

The bill raises broader questions about pharmacist recognition as frontline care providers—not mere medication dispensers.

First-line trastuzumab deruxtecan significantly delayed disease progression in HER2-mutant advanced NSCLC.

Adding family-based behavioral treatment to standard care nearly doubled clinically meaningful weight loss in kids in the TEAM UP trial.

The all-oral combination of osimertinib and savolitinib significantly improved progression-free and overall survival following osimertinib resistance.

Topiramate, an antiseizure medication, has an off-label indication for cocaine use disorder and it received a conditional recommendation with a low certainty of evidence.

The agency's decision pairs a new self-administration device with label language tying LDL-C lowering to cardiovascular outcomes.

New research shows COVID vaccine hesitancy wanes, but burnout rises.

Every diagnosis comes with a workload for patients.